Roivant Sciences Ltd.
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed May 20, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)The following documents are filed as part of this Annual Report on Form 10-K:
- Financial Statements:
For a list of the consolidated financial statements included herein, see “Index to Consolidated Financial Statements” under Part II, Item 8 of this Annual Report on Form 10-K.
- Financial Statement Schedules:
All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.
(b)Exhibits required by Item 601 of Regulation S-K:
The exhibits listed in the accompanying Exhibit Index are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K.
Exhibits
| ExhibitNumber | Incorporated by Reference | ||||
|---|---|---|---|---|---|
| Description | Form | File No. | Exhibit | Filing Date | |
| 2.1* | Business Combination Agreement, dated as of May 1, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc. | 10-K | 001-40782 | 2.1 | June 28, 2022 |
| 2.2* | Amendment No. 1 to the Business Combination Agreement, dated June 9, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc. | 10-K | 001-40782 | 2.9 | June 28, 2022 |
| 2.3#†* | Agreement and Plan of Merger, dated September 17, 2024, by and among Dermavant Sciences Ltd., Organon & Co., Organon Bermuda Ltd. and Roivant Sciences Ltd. | 8-K | 001-40782 | 2.1 | September 23, 2024 |
| 3.1* | Memorandum of Association of Roivant Sciences Ltd. | S-4/A | 333-256165 | 3.1 | July 1, 2021 |
| 3.2* | Amended and Restated Bye-laws of Roivant Sciences Ltd. | 8-K | 001-40782 | 3.1 | October 1, 2021 |
| 4.1* | Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 | — | — | — | Filed herewith |
| 10.1* | Third Amended and Restated Registration Rights Agreement, dated as of May 1, 2021, by and among Roivant Sciences Ltd. and the parties thereto | 10-K | 001-40782 | 10.1 | June 28, 2022 |
| 10.2* | Sponsor Support Agreement, dated as of May 1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. | 10-K | 001-40782 | 10.3 | June 28, 2022 |
|---|---|---|---|---|---|
| 10.3#* | License Agreement, dated as of December 19, 2017, by and between HanAll Biopharma Co., Ltd. and Roivant Sciences GmbH | 8-K | 001-38906 | 10.6 | December 20, 2019 |
| 10.4#* | Cross License Agreement, dated as of April 11, 2018, by and between Genevant Sciences Ltd. and Arbutus Biopharma Corporation | 10-Q | 001-34949 | 10.3 | August 7, 2020 |
| 10.5#* | First Amendment to Cross License Agreement, dated as of June 27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation | 10-Q | 001-34949 | 10.4 | August 7, 2020 |
| 10.6#* | Second Amendment to Cross License Agreement, dated as of June 27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation | 10-Q | 001-34949 | 10.5 | August 7, 2020 |
| 10.7* | Form of Indemnity Agreement | S-4/A | 333-256165 | 10.24 | July 1, 2021 |
| 10.8*^ | Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan | S-4 | 333-256165 | 10.25 | May 14, 2021 |
| 10.9*^ | Roivant Sciences Ltd. 2021 Equity Incentive Plan | S-8 | 333-260173 | 99.1 | October 8, 2021 |
| 10.10*^ | Executive Employment Agreement between Roivant Sciences, Inc. and Matthew Gline, dated as of May 14, 2021 | S-4 | 333-256165 | 10.28 | May 14, 2021 |
| 10.11*^ | Executive Employment Agreement between Roivant Sciences, Inc. and Eric Venker, dated as of May 14, 2021 | S-4 | 333-256165 | 10.29 | May 14, 2021 |
| 10.12* | Amendment No. 1 to the Support Agreement, dated as of June 9, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. | 10-K | 001-40782 | 10.28 | June 28, 2022 |
| 10.13* | Amendment No. 2 to the Support Agreement, dated as of September 30, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. | 8-K | 001-40782 | 10.1 | October 1, 2021 |
| 10.14*^ | Amended & Restated Roivant Sciences Ltd. Employee Stock Purchase Plan | 10-K | 001-40782 | 10.27 | June 28, 2023 |
| 10.15#* | Third Amendment to Cross License Agreement, dated December 9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation | S-1 | 333-261853 | 10.37 | December 22, 2021 |
|---|---|---|---|---|---|
| 10.16#†* | Investor Rights Agreement, dated as of September 13, 2021, by and among Priovant Holdings, Inc., Roivant Sciences Ltd. and Pfizer Inc. | 10-K | 001-40782 | 10.36 | June 28, 2022 |
| 10.17#†* | License and Collaboration Agreement, dated as of September 13, 2021, by and between Pfizer Inc. and Priovant, Inc. | 10-K | 001-40782 | 10.37 | June 28, 2022 |
| 10.18#* | Amendment No. 1 to License and Collaboration Agreement, dated as of June 10, 2022, by and between Pfizer Inc. and Priovant, Inc. | 10-K | 001-40782 | 10.38 | June 28, 2022 |
| 10.19*^ | Employment Agreement between Roivant Sciences, Inc. and Mayukh Sukhatme, dated as of May 19, 2020 | S-1/A | 333-260619 | 10.39 | July 28, 2022 |
| 10.20* | Form of Stock Option Grant Notice under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan | 10-K | 001-40782 | 10.39 | June 28, 2023 |
| 10.21* | Form of Restricted Stock Unit Award Grant Notice under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan | 10-K | 001-40782 | 10.40 | June 28, 2023 |
| 10.22* | Form of Performance Option Grant Notice under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan | 10-K | 001-40782 | 10.41 | June 28, 2023 |
| 10.23* | Form of Capped Value Appreciation Right Award Grant Notice under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan | 10-K | 001-40782 | 10.42 | June 28, 2023 |
| 10.24* | Form of Stock Option Grant Notice under the Roivant Sciences Ltd. 2021 Equity Incentive Plan | 10-K | 001-40782 | 10.43 | June 28, 2023 |
| 10.25* | Form of Restricted Stock Unit Award Grant Notice under the Roivant Sciences Ltd. 2021 Equity Incentive Plan | 10-K | 001-40782 | 10.44 | June 28, 2023 |
| 10.26*^ | Employment Agreement between Roivant Sciences, Inc. and Rakhi Kumar, dated as of June 5, 2023 | 10-Q | 001-40782 | 10.44 | August 9, 2024 |
| 10.27#*^ | Employment Agreement between Roivant Sciences, Inc. and Richard Pulik, dated as of August 31, 2021 | 10-Q | 001-40782 | 10.43 | August 9, 2024 |
| 10.28#†* | License Agreement by and between Bayer Aktiengesellschaft and Pulmovant, Inc., dated as of July 27, 2023 | 10-Q | 001-40782 | 10.45 | November 12, 2024 |
| 10.29#†* | First Amendment to the License Agreement by and between Bayer Aktiengesellschaft and Pulmovant, Inc., dated as of September 22, 2023 | 10-Q | 001-40782 | 10.46 | November 12, 2024 |
| 10.30* | Form of Performance Restricted Stock Unit Award Grant Notice under the Roivant Sciences Ltd. 2021 Equity Incentive Plan | 10-K | 001-40782 | 10.36 | May 29, 2025 |
| 10.31†^* | Separation Agreement and General Release between Roivant Sciences, Inc. and Rakhi Kumar | 10-K | 001-40782 | 10.37 | May 29, 2025 |
| 10.32†*^ | Consulting Agreement between Roivant Sciences, Inc. and Rakhi Kumar | 10-K | 001-40782 | 10.38 | May 29, 2025 |
| 10.33*^ | Letter of Offer for Employment between Roivant Sciences, Inc. and Jennifer Humes, dated as of February 7, 2025. | 10-Q | 001-40782 | 10.1 | August 11, 2025 |
| 10.34*^ | Amended & Restated Executive Employment Agreement between Roivant Sciences, Inc. and Eric Venker, dated as of July 28, 2025. | 10-Q | 001-40782 | 10.2 | August 11, 2025 |
| 10.35†*^ | Employment Agreement between Immunovant, Inc. and Eric Venker, dated as of July 28, 2025. | 10-Q | 001-40782 | 10.3 | August 11, 2025 |
| 10.36*^ | Form of Capped Value Appreciation Right Award Grant Notice and Award Agreement under 2019 Equity Incentive Plan of Immunovant, Inc. | 10-Q | 001-40782 | 10.4 | August 11, 2025 |
| 10.37*^ | Forms of Option Grant Notices and Option Agreements under 2019 Equity Incentive Plan of Immunovant, Inc. | 10-Q | 001-40782 | 10.5 | August 11, 2025 |
| 10.38*^ | 2019 Equity Incentive Plan of Immunovant, Inc. | 10-Q | 001-40782 | 10.6 | August 11, 2025 |
| 10.39†*^ | Special Equity Award Opportunity Letter, dated as of July 26, 2024. | 10-Q | 001-40782 | 10.7 | August 11, 2025 |
| 10.40#†* | Settlement Agreement, dated as of March 3, 2026, by and among Genevant Sciences GmbH, Arbutus Biopharma Corp., Genevant Sciences Ltd., Moderna, Inc. and ModernaTX, Inc. | 8-K/A | 001-40782 | 10.1 | March 23, 2026 |
| 19* | Insider Trading Policy | 10-K | 001-40782 | 19 | May 29, 2025 |
| 21.1 | List of Subsidiaries of Roivant Sciences Ltd. | — | — | — | Filed herewith |
| 23.1 | Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm of Roivant Sciences Ltd. | — | — | — | Filed herewith |
| 24.1 | Power of Attorney (included on signature page) | — | — | — | Filed herewith |
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | — | — | — | Filed herewith |
| 97* | Roivant Sciences Ltd. Compensation Recoupment Policy | 10-K | 001-40782 | 97 | May 30, 2024 |
| 101.INS | Inline XBRL Instance Document | — | — | — | Filed herewith |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | — | — | — | Filed herewith |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | — | — | — | Filed herewith |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | — | — | — | Filed herewith |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | — | — | — | Filed herewith |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | — | — | — | Filed herewith |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | — | — | — | Filed herewith |
#Portions of this exhibit have been omitted because they are both (i) not material and (ii) would likely cause competitive harm to Roivant Sciences Ltd. if publicly disclosed.
†Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the Securities and Exchange Commission.
*Previously filed.
**In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for purpose of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.
^Management contract or compensatory plan or arrangement required to be filed as an exhibit to this Form 10-K pursuant to Item 15(b).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.